New York State Common Retirement Fund Sells 1,093 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

New York State Common Retirement Fund reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,828 shares of the company's stock after selling 1,093 shares during the period. New York State Common Retirement Fund owned about 0.06% of Medpace worth $6,587,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of MEDP. Iron Triangle Partners LP acquired a new stake in shares of Medpace during the third quarter worth about $64,371,000. Wellington Management Group LLP grew its position in shares of Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after purchasing an additional 109,886 shares during the period. DF Dent & Co. Inc. increased its stake in shares of Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company's stock valued at $53,841,000 after acquiring an additional 105,659 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new position in Medpace during the third quarter worth approximately $23,321,000. Finally, International Assets Investment Management LLC grew its position in Medpace by 38,432.9% during the third quarter. International Assets Investment Management LLC now owns 57,414 shares of the company's stock valued at $19,165,000 after acquiring an additional 57,265 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, Medpace currently has an average rating of "Hold" and an average price target of $381.44.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded up $1.21 on Friday, hitting $327.32. The stock had a trading volume of 425,874 shares, compared to its average volume of 296,299. The company has a market capitalization of $9.97 billion, a price-to-earnings ratio of 25.92, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36. The firm's 50 day moving average price is $342.66 and its 200-day moving average price is $345.44. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.